Effect of thiazolidinediones on body weight in patients with diabetes mellitus

American Journal of Medicine

Volumn 115, Issue 8 SUPPL. 1, 2003, Pages 42-48

  Fonseca, Vivian ^a,b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; INSULIN; METFORMIN;

BODY FAT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT PLANNING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0346219295     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.09.005     Document Type: Conference Paper

References (57)

1. Mokdad A.H., Ford E.S., Bowman B.A., et al. Diabetes trends in the US 1990-1998 . Diabetes Care. 23:2000;1278-1283.
2. Lebovitz H.E., Banerji M.A. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res. 56:2001;265-294.
3. Parulkar A.A., Pendergrass M.L., Granda-Ayala R., et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 134:2001;61-71.
4. Carey D.G., Jenkins A.B., Campbell L.V., et al. Abdominal fat and insulin resistance in normal and overweight women direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM . Diabetes. 45:1996;633-638.
5. Kissebah A.H., Krakower G.R. Regional adiposity and morbidity. Physiol Rev. 74:1994;761-811.
6. Arner P. Differences in lipolysis between human subcutaneous and omental adipose tissues. Ann Med. 27:1995;435-438.
7. Williamson J.R., Browning E.T., Scholz R. Control mechanisms of gluconeogenesis and ketogenesis. I. Effects of oleate on gluconeogenesis in perfused rat liver. J Biol Chem. 244:1969;4607-4616.
8. Chen X., Iqbal N., Boden G. The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest. 103:1999;365-372.
9. Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physicians. 111:1999;241-248.
10. Barzilai N., She L., Liu B.-Q., et al. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes. 48:1999;94-98.
11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329:1993;977-986.
12. Purnell J.Q., Hokanson J.E., Marcovina S.M., et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure. JAMA. 280:1998;140-146.
13. Williams K.V., Ervey J.R., Becker D., Orchard T.J. Improved glycemic control reduces the impact of weight gain on cardiovascular risk factors in type 1 diabetes. Diabetes Care. 22:1999;1084-1091.
14. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
15. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 352:1998;854-865.
16. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 346:2002;393-403.
17. Fonseca V., Rosenstock J., Patwardhan R., Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus a randomized controlled trial . JAMA. 283:2000;1695-1702.
18. Gomez-Perez F.J., Fanghanel-Salmon G., Antonio Barbosa J., et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev. 18:2002;127-134.
19. Avilés-Santa L., Sinding J., Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus a randomized, double-blind, placebo-controlled trial . Ann Intern Med. 131:1999;182-188.
20. Yki-Järvinen H., Ryysy L., Nikkilä K., et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus a randomized, controlled trial . Ann Intern Med. 130:1999;389-396.
21. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes scientific review . JAMA. 287:2002;360-372.
22. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 131:1999;281-303.
23. Fonseca V., Foyt H.L., Shen K., Whitcomb R. Long-term effects of troglitazone open-label extension studies in type 2 diabetic patients . Diabetes Care. 23:2000;354-359.
24. Mori Y., Murakawa Y., Okada K., et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care. 22:1999;908-912.
25. Patel J., Anderson R.J., Rappaport E.B. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes a twelve-week, randomized, placebo-controlled study . Diabetes Obes Metab. 1:1999;165-172.
26. Chawla A., Schwarz E.J., Dimaculangan D.D., Lazar M.A. Peroxisome proliferator-activated receptor (PPAR) γ adipose-predominant expression and induction early in adipocyte differentiation . Endocrinology. 135:1994;798-800.
27. Spiegelman B.M. PPAR-γ adipogenic regulator and thiazolidinedione receptor . Diabetes. 47:1998;507-514.
28. Pelton P.D., Zhou L., Demarest K.T., Burris T.P. PPARγ activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. Biochem Biophys Res Commun. 261:1999;456-458.
29. Albrektsen T., Frederiksen K.S., Holmes W.E., et al. Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation. Diabetes. 51:2002;1042-1051.
30. Lefebvre A.-M., Laville M., Vega N., et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes. 47:1998;98-103.
31. Shimizu H., Tsuchiya T., Sato N., et al. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care. 21:1998;1470-1474.
32. Kelly I.E., Han T.S., Walsh K., Lean M.E.J. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care. 22:1999;288-293.
33. Nakamura T., Funahashi T., Yamashita S., et al. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation double-blind placebo-controlled trial . Diabetes Res Clin Pract. 54:2001;181-190.
34. Akazawa S., Sun F., Ito M., et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care. 23:2000;1067-1071.
35. Okuno A., Tamemoto H., Tobe K., et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest. 101:1998;1354-1361.
36. Miyazaki Y., Mahankali A., Matsuda M., et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 87:2002;2784-2791.
37. Carey D.G., Cowin G.J., Galloway G.J., et al. Sensitivity effect of rosiglitazone on insulin and body fat composition in type 2 diabetic patients. Obes Res. 10:2002;1008-1015.
38. Kelley D.E., McKolanis T.M., Kelley C.A. Comparative effects of rosiglitazone and metformin on fatty liver and visceral adiposity in type 2 diabetes mellitus [abstract]. Diabetes. 51:(suppl 2):2002;A35.
39. Virtanen K.A., Hällsten K., Parkkola R., et al. Different effects of rosiglitazone and metformin on adipose tissue glucose uptake in type 2 diabetes [abstract]. Diabetes. 51:(suppl 2):2002;A145.
40. Muto S., Miyata Y., Imai M., Asano Y. Troglitazone stimulates basolateral rheogenic Na+/HCO3- cotransport activity in rabbit proximal straight tubules. Exp Nephrol. 9:2001;191-197.
41. Yoshimoto T., Naruse M., Nishikawa M., et al. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol. 272:1997;E989-E996.
42. Hosokawa M., Tsukada H., Fukuda K., et al. Troglitazone inhibits bicarbonate secretion in rat and human duodenum. J Pharmacol Exp Ther. 290:1999;1080-1084.
43. Walker A.B., Naderali E.K., Chattington P.D., et al. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes. 47:1998;810-814.
44. Emoto M., Anno T., Sato Y., et al. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes. 50:2001;1166-1170.
45. Buch H.N., Baskar V., Barton D.M., et al. Combination of insulin and thiazolidinedione therapy in massively obese patients with type 2 diabetes. Diabet Med. 19:2002;572-574.
46. Gokcel A., Karakose H., Ertorer E.M., et al. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care. 24:2001;1957-1960.
47. Hollander P.A., Elbein S.C., Hirsch I.B., et al. Role of orlistat in the treatment of obese patients with type 2 diabetes a 1-year randomized double-blind study . Diabetes Care. 21:1998;1288-1294.
48. Kelley D.E., Bray G.A., Pi-Sunyer F.X., et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes a 1-year randomized controlled trial . Diabetes Care. 25:2002;1033-1041.
49. McNulty S.J., Ur E., Williams G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care. 26:2003;125-131.
50. Serrano-Rios M., Melchionda N., Moreno-Carretero E. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med. 19:2002;119-124.
51. Greenway F. Obesity medications and treatment of type 2 diabetes. Diabetes Technol Ther. 1:1999;277-287.
52. Finer N. Low-calorie diets and sustained weight loss. Obes Res. 9:(suppl 4):2001;290S-294S.
53. Williams K.V., Mullen M.L., Kelley D.E., Wing R.R. The effect of short periods of caloric restriction on weight loss and glycemic control in type 2 diabetes. Diabetes Care. 21:1998;2-8.
54. Hensrud D.D. Dietary treatment and long-term weight loss and maintenance in type 2 diabetes. Obes Res. 9:(suppl 4):2001;348S-353S.
55. Bastard J.-P., Hainque B., Dusserre E., et al. Peroxisome proliferator activated receptor-γ, leptin and tumor necrosis factor-α mRNA expression during very low calorie diet in subcutaneous adipose tissue in obese women. Diabetes Metab Res Rev. 15:1999;92-98.
56. Vidal-Puig A.J., Considine R.V., Jimenez-Liñan M., et al. Peroxisome proliferator-activated receptor gene expression in human tissues effects of obesity, weight loss, and regulation by insulin and glucocorticoids . J Clin Invest. 99:1997;2416-2422.
57. Asnani S., Richard B.C., Desouza C., Fonseca V. Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet. Curr Med Res Opin. 19:2003;609-613.